DiaMedica Therapeutics (DMAC) Accounts Payables (2017 - 2026)

DiaMedica Therapeutics' Accounts Payables history runs 10 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 118.51% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 118.51% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 56.91% from the prior year.
• Accounts Payables rose to $3.3 million in Q1 2026 per DMAC's latest filing, from $1.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $3.3 million in Q1 2026 and bottomed at $433000.0 in Q1 2022.
• The 5-year median for Accounts Payables is $926000.0 (2023), against an average of $1.2 million.
• Across the five-year window, Accounts Payables soared 311.09% in 2023 and plunged 59.78% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $734000.0 in 2022, then climbed by 26.16% to $926000.0 in 2023, then advanced by 1.51% to $940000.0 in 2024, then soared by 56.91% to $1.5 million in 2025, then soared by 123.25% to $3.3 million in 2026.
• Per Business Quant, the three latest DMAC Accounts Payables figures stand at $3.3 million (Q1 2026), $1.5 million (Q4 2025), and $1.9 million (Q3 2025).